Equities research analysts expect that Eyenovia Inc (NASDAQ:EYEN) will announce ($0.47) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Eyenovia’s earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.42). Eyenovia posted earnings per share of ($0.33) during the same quarter last year, which would indicate a negative year-over-year growth rate of 42.4%. The business is scheduled to issue its next earnings results on Tuesday, August 13th.
On average, analysts expect that Eyenovia will report full year earnings of ($1.80) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.62). For the next financial year, analysts expect that the firm will post earnings of ($1.54) per share, with EPS estimates ranging from ($1.96) to ($1.06). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Eyenovia.
Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.01.
Several brokerages recently commented on EYEN. Oppenheimer started coverage on shares of Eyenovia in a research note on Wednesday, April 24th. They set an “outperform” rating and a $9.00 price target on the stock. HC Wainwright set a $14.00 target price on shares of Eyenovia and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, Zacks Investment Research downgraded shares of Eyenovia from a “hold” rating to a “sell” rating in a report on Tuesday, February 26th.
Shares of EYEN opened at $4.79 on Monday. Eyenovia has a twelve month low of $2.40 and a twelve month high of $8.49. The firm has a market capitalization of $58.89 million, a PE ratio of -2.63 and a beta of 1.59.
A number of hedge funds have recently added to or reduced their stakes in EYEN. Hilltop Holdings Inc. bought a new stake in Eyenovia in the 1st quarter valued at $210,000. Northern Trust Corp acquired a new stake in Eyenovia in the first quarter valued at about $118,000. BlackRock Inc. boosted its stake in Eyenovia by 1,689.6% in the first quarter. BlackRock Inc. now owns 16,500 shares of the company’s stock valued at $99,000 after buying an additional 15,578 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Eyenovia during the fourth quarter worth about $36,000. Finally, Vanguard Group Inc bought a new position in shares of Eyenovia during the third quarter worth about $157,000. 10.79% of the stock is currently owned by hedge funds and other institutional investors.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Recommended Story: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.